Rob E. Aarnoutse

10.5k total citations · 1 hit paper
194 papers, 6.6k citations indexed

About

Rob E. Aarnoutse is a scholar working on Infectious Diseases, Epidemiology and Pharmacology. According to data from OpenAlex, Rob E. Aarnoutse has authored 194 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 140 papers in Infectious Diseases, 93 papers in Epidemiology and 51 papers in Pharmacology. Recurrent topics in Rob E. Aarnoutse's work include Tuberculosis Research and Epidemiology (87 papers), Pneumocystis jirovecii pneumonia detection and treatment (46 papers) and Antibiotics Pharmacokinetics and Efficacy (45 papers). Rob E. Aarnoutse is often cited by papers focused on Tuberculosis Research and Epidemiology (87 papers), Pneumocystis jirovecii pneumonia detection and treatment (46 papers) and Antibiotics Pharmacokinetics and Efficacy (45 papers). Rob E. Aarnoutse collaborates with scholars based in Netherlands, United States and Indonesia. Rob E. Aarnoutse's co-authors include Martin J. Boeree, David M. Burger, Reinout van Crevel, Rovina Ruslami, André van der Ven, Bachti Alisjahbana, Alma Tostmann, Gibson Kibiki, Wiel C.M. de Lange and Roger J. M. Brüggemann and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Rob E. Aarnoutse

181 papers receiving 6.4k citations

Hit Papers

Antituberculosis drug‐induced hepatotoxicity: Concise up‐... 2007 2026 2013 2019 2007 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Antituberculosis drug‐induced hepatotoxicity: Concise up‐to‐date review
    2007 576 citations Martin J. Boeree, Rob E. Aarnoutse et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rob E. Aarnoutse Netherlands 45 4.5k 2.9k 1.3k 1.1k 807 194 6.6k
Helen McIlleron South Africa 43 4.4k 1.0× 2.4k 0.8× 851 0.7× 1.3k 1.2× 566 0.7× 181 5.6k
William J. Burman United States 47 4.8k 1.1× 3.6k 1.3× 1.3k 1.0× 727 0.7× 236 0.3× 121 6.8k
Martin J. Boeree Netherlands 51 5.4k 1.2× 4.9k 1.7× 1.5k 1.2× 529 0.5× 664 0.8× 165 7.4k
Giovanni Di Perri Italy 43 3.8k 0.9× 2.2k 0.8× 421 0.3× 856 0.8× 262 0.3× 418 7.7k
Kelly E. Dooley United States 36 3.5k 0.8× 2.4k 0.8× 1.3k 1.0× 418 0.4× 229 0.3× 141 4.6k
Charles A. Peloquin United States 57 7.8k 1.7× 5.9k 2.0× 2.0k 1.6× 3.2k 2.9× 1.2k 1.4× 317 11.7k
Tjip S. van der Werf Netherlands 49 3.2k 0.7× 4.3k 1.5× 1.3k 1.0× 896 0.8× 300 0.4× 312 8.1k
Laurent A. Décosterd Switzerland 50 3.8k 0.9× 1.5k 0.5× 367 0.3× 1.2k 1.1× 768 1.0× 270 10.1k
Dario Cattaneo Italy 38 1.6k 0.4× 810 0.3× 1.1k 0.8× 714 0.6× 230 0.3× 233 5.8k
David M. Burger Netherlands 56 9.0k 2.0× 3.3k 1.1× 496 0.4× 1.1k 1.0× 784 1.0× 497 13.4k

Countries citing papers authored by Rob E. Aarnoutse

Since Specialization
Citations

This map shows the geographic impact of Rob E. Aarnoutse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rob E. Aarnoutse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rob E. Aarnoutse more than expected).

Fields of papers citing papers by Rob E. Aarnoutse

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rob E. Aarnoutse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rob E. Aarnoutse. The network helps show where Rob E. Aarnoutse may publish in the future.

Co-authorship network of co-authors of Rob E. Aarnoutse

This figure shows the co-authorship network connecting the top 25 collaborators of Rob E. Aarnoutse. A scholar is included among the top collaborators of Rob E. Aarnoutse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rob E. Aarnoutse. Rob E. Aarnoutse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Santoso, Prayudi, Vycke Yunivita, Lindsey H. M. te Brake, et al.. (2025). Pharmacogenetics and Pharmacokinetics of Moxifloxacin in MDR-TB Patients in Indonesia: Analysis for ABCB1 and SLCO1B1. Antibiotics. 14(2). 204–204. 2 indexed citations
2.
Seddon, James A., Felicia C. Chow, Caryn M. Upton, et al.. (2025). Intensified Treatment of Tuberculous Meningitis in Adults: A Systematic Review and Meta-analysis. Open Forum Infectious Diseases. 12(10). ofaf503–ofaf503.
3.
Pistorius, Arthur M. A., Rob ter Heine, Tim Frenzel, et al.. (2025). Population pharmacokinetics and optimized dosing of cefuroxime in critically ill patients. British Journal of Clinical Pharmacology. 91(9). 2755–2761.
4.
Upton, Caryn M., Andreas H. Diacon, Martin J. Boeree, et al.. (2025). Cerebrospinal fluid penetration of cycloserine/terizidone and clofazimine in patients with pulmonary TB. Antimicrobial Agents and Chemotherapy. 69(12). e0093125–e0093125.
5.
Heinrich, Norbert, Veronique de Jager, Patrick Phillips, et al.. (2025). Population pharmacokinetics and exposure–response relationship of the antituberculosis drug BTZ-043. Journal of Antimicrobial Chemotherapy. 80(5). 1315–1323. 1 indexed citations
6.
Magis‐Escurra, Cecile, Martin J. Boeree, Rob E. Aarnoutse, et al.. (2024). Evaluation of a national multidisciplinary meeting for non-tuberculous mycobacterial disease. SHILAP Revista de lepidopterología. 1(6). 279–281. 2 indexed citations
7.
Jager, Nynke G L, et al.. (2024). Influence of ultrafiltration conditions on the measurement of unbound drug concentrations: flucloxacillin as an example. Journal of Antimicrobial Chemotherapy. 79(5). 1187–1190. 1 indexed citations
8.
Svensson, Elin M., Lindsey H. M. te Brake, Reinout van Crevel, et al.. (2024). A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease. Journal of Antimicrobial Chemotherapy. 79(12). 3100–3108. 5 indexed citations
9.
Coenen, Marieke J. H., Rob E. Aarnoutse, Willem A. Nolen, et al.. (2024). A genetic risk score to predict treatment nonresponse in psychotic depression. Translational Psychiatry. 14(1). 132–132. 2 indexed citations
10.
Phillips, Patrick, Caryn M. Upton, Jakko van Ingen, et al.. (2023). Early bactericidal activity studies for pulmonary tuberculosis: A systematic review of methodological aspects. International Journal of Antimicrobial Agents. 61(5). 106775–106775. 8 indexed citations
11.
Dorlo, Thomas P. C., et al.. (2023). Power to identify exposure‐response relationships in phase IIa pulmonary tuberculosis trials with multi‐dimensional bacterial load modeling. CPT Pharmacometrics & Systems Pharmacology. 13(3). 374–385. 1 indexed citations
12.
13.
Wasmann, Roeland E., Chishala Chabala, Helena Rabie, et al.. (2023). Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis. PLoS Medicine. 20(11). e1004303–e1004303. 4 indexed citations
14.
Musaazi, Joseph, Allan Buzibye, Rob E. Aarnoutse, et al.. (2023). Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicin. Antimicrobial Agents and Chemotherapy. 67(11). e0043023–e0043023. 4 indexed citations
15.
Boeree, Martin J., Cécile Magis-Escurra, Wouter Hoefsloot, et al.. (2022). Interleukin-1 receptor antagonist anakinra as treatment for paradoxical responses in HIV-negative tuberculosis patients: A case series. Med. 3(9). 603–611.e2. 11 indexed citations
16.
17.
18.
Lempers, Vincent J., Lisa C. Martial, Michiel F. Schreuder, et al.. (2015). Drug-interactions of azole antifungals with selected immunosuppressants in transplant patients: strategies for optimal management in clinical practice. Current Opinion in Pharmacology. 24. 38–44. 53 indexed citations
19.
Mouton, Johan W. & Rob E. Aarnoutse. (2014). [Therapeutic drug monitoring of antimicrobials].. PubMed. 158. A7520–A7520.
20.
Burger, David M., Patricia W. H. Hugen, Peter Reiss, et al.. (2003). Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS. 17(8). 1157–1165. 119 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Helen McIlleron Breakdown of academic impact, for papers by William J. Burman Breakdown of academic impact, for papers by Martin J. Boeree Breakdown of academic impact, for papers by Giovanni Di Perri Breakdown of academic impact, for papers by Kelly E. Dooley Breakdown of academic impact, for papers by Charles A. Peloquin Breakdown of academic impact, for papers by Tjip S. van der Werf Breakdown of academic impact, for papers by Laurent A. Décosterd Breakdown of academic impact, for papers by Dario Cattaneo Breakdown of academic impact, for papers by David M. Burger
Rankless by CCL
2026